Renaissance Technologies
MGX icon

Renaissance Technologies’s Metagenomi Therapeutics MGX Stock Holding History

Renaissance Technologies’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
787,900
+159,500
+25% +$248K ﹤0.01% 2243
2025
Q4 		$1.02M Buy
628,400
+461,400
+276% +$999K ﹤0.01% 2272
2025
Q3 		$396K Buy
167,000
+48,000
+40% +$97.4K ﹤0.01% 2886
2025
Q2 		$176K Buy
119,000
+19,400
+19% +$30.4K ﹤0.01% 3195
2025
Q1 		$135K Sell
99,600
-54,200
-35% -$129K ﹤0.01% 3149
2024
Q4 		$555K Sell
153,800
-28,300
-16% -$68.3K ﹤0.01% 2794
2024
Q3 		$395K Buy
+182,100
New +$632K ﹤0.01% 2881

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies's MGX Position: Q1 2026 in Review

Renaissance Technologies increased its Metagenomi Therapeutics (MGX) stake by 25% in Q1 2026, buying an estimated $248K and bringing the position to 787,900 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

Renaissance Technologies first reported a position in MGX in Q3 2024 and has held it in 7 quarters since. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Renaissance Technologies held 787,900 shares of Metagenomi Therapeutics worth $1.06M as of Q1 2026.
  • Renaissance Technologies bought 159,500 Metagenomi Therapeutics shares in Q1 2026, an estimated $248K.
  • Metagenomi Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2243 holding.
  • Renaissance Technologies first reported a position in Metagenomi Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.